Archives
- 2026-11
- 2026-10
- 2026-09
- 2026-08
- 2026-07
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
EPZ-6438 in HPV-Associated Cervical Cancer
2026-10-16
A 2025 study examined EPZ-6438 and ZLD1039 as EZH2 inhibitors in HPV-positive and HPV-negative cervical cancer models. Its findings support a preclinical association between EZH2 inhibition, reduced proliferation, apoptosis, G0/G1 arrest, and changes in viral, tumour-suppressor, and epithelial markers, but the evidence remains mainly cellular and the in vivo component was preliminary.
EGFP-Targeting sgRNAs: What Is Documented
2026-10-15
The APExBIO product entry identifies R2997 as three EGFP-targeting single-guide RNAs associated with HeLa and lists 3 μmol per guide. That information supports a limited, conceptual description of guide-directed genome targeting and possible EGFP-signal readouts, but it does not establish guide sequences, nuclease pairing, target-site performance, editing outcomes, or use in a defined HeLa derivative. No identity-matched research evidence is available.
What OA Biomarker Comparisons Actually Show
2026-10-15
Li et al. identified JUN and MYC as acetylation-related osteoarthritis biomarkers through integrated transcriptomic analysis and protein-level validation. The evidence supports reproducible association with osteoarthritis in the analyzed cohorts, but does not yet establish that altered acetylation causes the observed expression changes, that either marker is clinically ready for diagnosis, or that the named lysis buffer has comparative performance advantages.
Sulfo-Cy5 NHS Ester: Evidence and Scope
2026-10-14
APExBIO describes Sulfo-Cy5 NHS ester, also termed Sulfo-Cyanine5 Succinimidyl Ester, as a sulfonated, water-compatible NHS-ester fluorophore for labeling amine-containing biomolecules. The available evidence supports a product-identity and measurement overview, but not independent claims about labeling efficiency, target specificity, comparative performance, or clinical applicability.
Neuroblastoma PDT and RBCM Nanocarriers
2026-10-14
A supplied 2026 study reports that iRGD-functionalized red-blood-cell membrane vesicles improved delivery of the photosensitizer TPOR and enhanced photodynamic effects in neuroblastoma cell and in vivo models. The findings are promising but remain preclinical, with important limitations in model scope, reporting detail, mechanism, safety, and translation to patients.
Lanthanum, Lipophagy, and the Limits of Zebrafish Evidence
2026-10-13
A 2026 zebrafish study links chronic lanthanum chloride exposure with hepatic steatosis and impaired lipophagy through an AMPK-related signaling model. The findings are mechanistically suggestive but remain limited in their relevance to human exposure, sex differences, dose response, and direct causal attribution.
Monomeric Aβ and Microglial Immune Homeostasis
2026-10-13
This editorial examines a bioRxiv preprint proposing that monomeric amyloid-β can restrain inflammatory microglial activity through an APP–heterotrimeric G-protein pathway during cortical development. The findings are mechanistically suggestive but remain bounded by the preprint’s developmental models, incomplete reporting in the supplied summary, and the distinction between monomeric Aβ and other amyloid species associated with Alzheimer’s disease.
Acifran and HCAR Structure: What the Study Shows
2026-10-12
A 2025 cryo-EM and cellular-signaling study examined how agonists recognize HCAR3 and HCAR2, including Acifran. The findings provide a structural framework for ligand selectivity, but they do not establish Acifran as an HCAR3-selective medicine, demonstrate clinical benefit, or resolve how receptor binding translates into whole-organism lipid regulation.
Mycophenolic Acid in Whole-Blood Immunometabolism
2026-10-12
A source-grounded overview of how mycophenolic acid fits into whole-blood immunometabolism research, emphasizing the reported cytokine findings, evidence limits, provenance, and boundaries of interpretation.
TaSERL2–TaBZR2 Control of Wheat Heat Tolerance
2026-10-11
The reference study identifies a TaSERL2–TaBZR2 regulatory module that links receptor-like kinase activity, transcription-factor stability, and wheat heat tolerance. Its central finding is that heat stress reduces TaSERL2-dependent inhibition of TaBZR2, supporting a phosphorylation-sensitive mechanism that operates beyond the canonical BIN2-centered brassinosteroid model.
BIRB 796 and the Logic of p38α Signaling
2026-10-10
Explore how BIRB 796 (Doramapimod) can be interpreted beyond simple kinase blockade, with a focus on allosteric control, phosphatase access, cytokine biology, and evidence limitations. This article connects product data with a 2024 p38α dephosphorylation study while distinguishing mechanistic insight from demonstrated therapeutic efficacy.
SNAI1 Drives EMT and Stemness in Thymic Tumors
2026-10-09
A 2024 study identifies SNAI1 as a transcriptional hub associated with invasive thymic epithelial tumors and links it mechanistically to the PIK3R2/phosphorylated EphA2 axis. The findings connect epithelial-mesenchymal transition, cancer stem cell-like behavior, and macrophage-state changes, while supporting SNAI1 as a preliminary therapeutic research target rather than a clinically validated intervention.
β-Pseudouridine in RNA Vaccine Research
2026-10-09
β-Pseudouridine is a C-glycoside isomer of uridine with important roles in RNA structure and translation. This evidence-focused analysis distinguishes its molecular effects from the platform-level findings of a 2026 self-amplifying RNA influenza vaccine study.
FDA Drug Screening Identifies Lopinavir for MERS-CoV
2026-10-08
A 2014 study screened 348 FDA-approved compounds and identified four small molecules, including Lopinavir, that inhibited MERS-CoV replication in cell culture at low-micromolar concentrations. The findings support phenotypic drug repurposing as an early discovery strategy, while also showing why cell-culture activity must not be treated as evidence of clinical efficacy.
scaRNA1, Splicing, and Genotyping Evidence
2026-10-08
A source-grounded overview of scaRNA1 disruption, U2 pseudouridylation, transcriptome changes, and the limited but potentially complementary role of mouse genotyping in related biomedical research.